The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Advanced Asthma — Biologic Therapies

Targeted biologic agents for severe uncontrolled asthma including anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα (dupilumab), and anti-TSLP (tezepelumab) tailored to type 2 vs non-type 2 inflammatory phenotype.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Advanced Asthma — Biologic Therapies?

Asthma biologics revolutionized treatment of severe uncontrolled asthma (Step 5 GINA, eosinophilic or allergic phenotype) by targeting specific inflammatory pathways. Indications include severe asthma uncontrolled despite high-dose ICS-LABA, frequent exacerbations requiring oral corticosteroids, oral corticosteroid dependence, severe asthma with type 2 inflammation biomarkers (eosinophils, FeNO, total IgE), and atopic comorbidities (atopic dermatitis, nasal polyps).

Mechanism-specific agents include omalizumab (Xolair, anti-IgE) for moderate-severe allergic asthma with elevated total IgE 30-1500 IU/mL and perennial allergen sensitization; mepolizumab (Nucala) and reslizumab (Cinqair) (anti-IL-5) blocking eosinophil maturation; benralizumab (Fasenra) targeting IL-5Rα for direct eosinophil depletion via NK cell-mediated apoptosis; dupilumab (Dupixent, anti-IL-4Rα) blocking IL-4 and IL-13 signaling; and tezepelumab (Tezspire, anti-TSLP) targeting epithelial alarmin upstream of type 2 and non-type 2 inflammation.

Selection considers asthma phenotype (eosinophilic, allergic, type 2 high), biomarker profile (peripheral eosinophils >150-300/μL, FeNO >25 ppb, total IgE), atopic comorbidities (dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps), and patient factors (age, dosing convenience). Tezepelumab's broad efficacy across phenotypes (including non-eosinophilic) makes it option for severe asthma regardless of biomarkers. Outcomes include 50-60% exacerbation reduction, oral corticosteroid sparing, FEV1 improvement, and quality of life enhancement.

Symptoms

Severe asthma uncontrolled on high-dose ICS-LABA (Step 5 GINA)
Frequent exacerbations requiring oral corticosteroids (≥2/year)
Continuous or frequent oral corticosteroid dependence
Severe asthma with eosinophilic inflammation (eosinophils >300/μL)
Severe allergic asthma with elevated total IgE
Severe asthma with comorbidities: atopic dermatitis, chronic rhinosinusitis with nasal polyps
Asthma exacerbations causing hospitalization or ICU admission

Risk Factors

Severe atopic phenotype with multiple aeroallergen sensitizations
Eosinophilic inflammation on sputum or peripheral blood
Elevated FeNO (>50 ppb) suggesting type 2 inflammation
Family history of atopy or severe asthma
Chronic rhinosinusitis with nasal polyps (Samter's triad if AERD)
Aspirin-exacerbated respiratory disease (AERD)
Occupational asthma with persistent symptoms

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe asthma symptoms despite maximal inhaled therapy
  • Frequent asthma exacerbations requiring oral corticosteroids
  • Daily symptoms or rescue inhaler use
  • Activity limitations or absent from work/school due to asthma
  • Continuous oral corticosteroid use with side effects (osteoporosis, diabetes, weight gain)
  • Severe asthma with atopic dermatitis or nasal polyps
  • ICU admission or near-fatal asthma exacerbation

Treatment Methods

01
Comprehensive asthma assessment: GINA classification, ACT score, exacerbation frequency, oral corticosteroid use, lung function (FEV1, FEV1/FVC, reversibility)
02
Phenotype assessment: total IgE, peripheral eosinophils, FeNO, allergen sensitization (skin prick or specific IgE), atopic comorbidities
03
Biologic selection algorithm: omalizumab for allergic asthma with elevated IgE; anti-IL-5/IL-5R for eosinophilic asthma; dupilumab for type 2 high with comorbidities; tezepelumab for severe asthma regardless of phenotype
04
Pre-biologic: tuberculosis screening, vaccination review, baseline asthma control, comorbidity assessment
05
Subcutaneous administration: variable dosing intervals (every 2 weeks for omalizumab to every 6 months for some), self-injection training
06
Monitoring: asthma control (ACT, exacerbations), lung function, oral corticosteroid tapering, biomarker trends, side effects
07
Long-term management: inhaled therapy continuation, biologic dose adjustment for response, switching biologics for inadequate response, allergen immunotherapy adjunct

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.